Phalguni Deswal
@Phalguni_GD
The US government has plans to invest over $5bn in the Project NextGen programme. Image Credit: PopTika / Shutterstock.
US Biomedical Advanced Research and Development Authority (BARDA) has partnered with Ireland-based
ICON
to conduct clinical trials of Covid-19 vaccine candidates selected as part of “Project NextGen”.
A part of the US Government’s Strategic Preparedness and Response division, BARDA has launched
Project NextGen to develop Covid-19 vaccines
and therapies for current and future strains. To achieve this, BARDA plans to leverage its public-private partnerships. The government has plans to
invest more than $5bn in the Project NextGen
programme.
Recommended Reports
Reports
LOA and PTSR Model - PBMC vaccine in Vaginal Cancer
GlobalData
Reports
LOA and PTSR Model - PBMC vaccine in Penile Cancer
GlobalData
View all
Companies Intelligence
ICON Plc
Emergent BioSolutions Inc
Regeneron GmbH
The U.S. government
View all
In June, the European Medicines Agency (EMA) identified the
need to update the Covid-19 vaccines
to include the XBB Omicron variant. The US Government seconded that sentiment, and last month, BARDA partnered with Regeneron to develop a
Covid-19 monoclonal antibody vaccine
candidate.
ICON’s government and public health solutions team
will conduct
a Phase IIb active comparator clinical trial to evaluate the efficacy of the next-generation Covid-19 vaccine, selected by BARDA, compared to the
currently approved/authorised vaccines
. The trial is expected to enrol 10,000 volunteers over a six-month period.
Although the Covid-19 trial activity has significantly decreased in the last two years, several trials have been initiated in 2023. As per GlobalData’s clinical trial database, more than 80 trials have been initiated for Covid-19 indication in the US and over 400 trials globally this year.
GlobalData is the parent company of
Pharmaceutical Technology
.
ICON previously partnered with Evergreen Therapeutics to
develop a Covid-19 drug therapy in 2021
. The Ireland-based company also has a
patent engagement platform
that increased patient outreach and enrolment.
ICON has previously partnered with BRADA to conduct a clinical trial for an anthrax vaccine, AV7909. The vaccine comprises
Emergent BioSolutions
’s Biothrax combined with an immune system stimulant or adjuvant.